Cited by 169Alzheimer's disease research and treatmentsNeuroinflammation and Neurodegeneration MechanismsNeurological Disease Mechanisms and Treatments

Nicotinamide treatment reduces the levels of oxidative stress, apoptosis, and PARP-1 activity in Aβ(1–42)-induced rat model of Alzheimer's disease

Turunc Bayrakdar, E., Uyanikgil, Y., Kanit, L., Koylu, E., Yalcin, A.·2014·Free Radical Research

Abstract

The underlying mechanisms of Alzheimer's Disease (AD) are still unclear. It is suggested that poly(ADP-ribose) polymerase-1 (PARP-1) overactivation can cause neuroinflammation and cell death. In this study we searched the effects of nicotinamide (NA), endogenous PARP-1 inhibitor, on oxidative stress, apoptosis, and the regulation of PARP-1 and nuclear factor kappa B (NF-κB) in amyloid beta peptide (1-42) (Aβ(1-42))-induced neurodegeneration. Sprague-Dawley rats were divided into four groups as control, Aβ(1-42), Aβ(1-42) + NA(100 and 500 mg/kg). All groups were stereotaxically injected bilaterally into the hippocampus with Aβ(1-42) or saline. After surgery NA administrations were made intraperitoneally (ip) for 7 days. In order to investigate the effects of Aβ(1-42) and NA, protein carbonyls, lipid peroxidation, reactive oxygen species (ROS) production, glutathione (GSH) levels, activities of antioxidant enzymes (catalase, superoxide dismutase, glutathione peroxidase), mitochondrial function, mRNA and protein levels of PARP-1, NF-κB, p53, Bax, and Bcl-2 were measured in specific brain regions such as cortex and hippocampus. Aβ(1-42) treatment only increased the oxidative stress parameters and caused decline in antioxidant enzyme activities, mitochondrial function, and GSH levels. Also, overexpression of PARP-1, NF-κB, p53, Bax, and the decreased levels of Bcl-2 were observed in Aβ(1-42)-treated group. NA treatments against Aβ(1-42)-upregulated Bcl-2 and downregulated PARP-1, NF-κB, p53, and Bax levels. NA treatments also decreased the oxidative stress parameters and elevated antioxidant enzyme activities, GSH levels, and mitochondrial function against Aβ(1-42) treatment. These data suggest that NA may have a therapeutic potential in neurodegenerative processes due to the decreased levels of oxidative stress, apoptosis, and PARP-1 activity.

Integrity signals

Registry

Crossref · 10.3109/10715762.2013.857018

Cites

94 of 94 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • In vivo studies using various Alzheimer disease and Parkinson disease models have shown that loss of PARP1 protects from brain dysfunctions and cognitive decline.

    “In vivo studies using various Alzheimer disease and Parkinson disease models have shown that loss of PARP1 protects from brain dysfunctions and cognitive decline170–174.”
  • PARP1 activation is associated with Alzheimer disease and Parkinson disease pathogenesis.

    “PARP1 activation is also associated with Alzheimer disease170,171 and Parkinson disease172,173 pathogenesis.”

Cites

Flagged first, then by citations

1 of the 95 references couldn’t be matched to a known paper.

Cited by

Sorted by citations

Authors
Turunc Bayrakdar, E., Uyanikgil, Y., Kanit, L., Koylu, E., & Yalcin, A.
Affiliations
Ege University (TR)
Venue
Free Radical Research
Published
2013-11-11
Volume
48
Issue
2
Pages
146-158
ISSN
  • 1029-2470 (ISSN-L)
  • 1071-5762
OpenAlex
W1980204153
Cited by
169
References
95
Citations by year
2026: 4 · 2025: 8 · 2024: 16 · 2023: 13 · 2022: 13 · 2021: 17 · 2020: 17 · 2019: 17 · 2018: 13 · 2017: 15 · 2016: 8 · 2015: 17 · 2014: 11
FWCI
8.33
Type
journal article
Language
en
Open access
closed
Locations
  • Free Radical Research (publishedVersion)
  • PubMed (publishedVersion)
Topics
  • Health Sciences › Medicine › Physiology › Alzheimer's disease research and treatments
  • Life Sciences › Neuroscience › Neurology › Neuroinflammation and Neurodegeneration Mechanisms
  • Life Sciences › Neuroscience › Neurology › Neurological Disease Mechanisms and Treatments
Keywords
nicotinamide, Alzheimer's disease, amyloid-beta 42, oxidative stress, apoptosis, PARP1, NF-κB, p53, Bax, Bcl-2, neuroinflammation, neurodegeneration, hippocampus, antioxidant enzymes, glutathione, mitochondrial function, reactive oxygen species, lipid peroxidation
MeSH terms
Poly(ADP-ribose) Polymerase Inhibitors, Poly (ADP-Ribose) Polymerase-1, Alzheimer Disease, Animals, Antioxidants, Catalase, Drug Evaluation, Preclinical, Glutathione, Glutathione Peroxidase, Hippocampus, Humans, Male, Malondialdehyde, Niacinamide, Peptide Fragments, Poly(ADP-ribose) Polymerases, Superoxide Dismutase, Synaptosomes, Lipid Peroxidation, Gene Expression, Amyloid beta-Peptides, NF-kappa B, Rats, Sprague-Dawley, Apoptosis, Reactive Oxygen Species, Oxidative Stress, Neuroprotective Agents, Apoptosis Regulatory Proteins, Rats

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review